UNITY Biotechnology Inc. recently announced receiving a notification from the Nasdaq Stock Market regarding non-compliance with continued listing requirements. As of June 18, 2025, the company's common stock had a closing bid price below the $1.00 per share minimum for the past 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). Additionally, as previously disclosed, the company's stockholders' equity fell below the required 10 million threshold as per Nasdaq Listing Rule 5450(b)(A)$. UNITY Biotechnology has submitted a compliance plan and an application to transfer to the Nasdaq Capital Market as it seeks to adhere to listing standards. The company has until December 15, 2025, to rectify these issues, with a potential extension available. Despite the current regulatory challenges, there is no immediate impact on the company's Nasdaq listing or stock trading.